Spero Therapeutics - SPRO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.33
  • Forecasted Upside: 194.57 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.15
▲ +0.15 (7.50%)

This chart shows the closing price for SPRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spero Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPRO

Analyst Price Target is $6.33
▲ +194.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Spero Therapeutics in the last 3 months. The average price target is $6.33, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 194.57% upside from the last price of $2.15.

This chart shows the closing price for SPRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Spero Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2022HC WainwrightLower TargetBuy$7.00 ➝ $6.00Low
9/22/2022Evercore ISIUpgradeIn-Line ➝ Outperform$8.00Low
8/15/2022HC WainwrightLower TargetBuy$10.00 ➝ $7.00Low
5/23/2022HC WainwrightLower TargetBuy$37.00 ➝ $10.00Medium
5/20/2022Berenberg BankDowngradeBuy ➝ HoldHigh
5/17/2022Cantor FitzgeraldLower Target$27.00 ➝ $5.00High
5/4/2022CowenDowngradeOutperform ➝ Market PerformMedium
4/18/2022HC WainwrightLower TargetBuy$43.00 ➝ $37.00High
3/21/2022HC WainwrightBoost TargetBuy$40.00 ➝ $43.00High
10/1/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
8/8/2021Evercore ISIReiterated RatingBuy$70.00Low
6/1/2021HC WainwrightReiterated RatingBuy$40.00Medium
1/22/2021HC WainwrightBoost TargetBuy$33.00 ➝ $40.00High
12/16/2020Berenberg BankInitiated CoverageBuy$47.00High
11/23/2020HC WainwrightBoost TargetBuy$28.00 ➝ $33.00High
10/25/2020OppenheimerReiterated RatingBuy$19.00High
9/29/2020Evercore ISIInitiated CoverageOutperformHigh
9/8/2020OppenheimerReiterated RatingBuy$20.00High
9/8/2020Stifel NicolausReiterated RatingBuy$21.00 ➝ $25.00High
8/31/2020OppenheimerReiterated RatingBuyHigh
6/2/2020HC WainwrightReiterated RatingBuy$28.00High
5/11/2020HC WainwrightBoost TargetBuy$25.00 ➝ $28.00High
5/8/2020OppenheimerInitiated CoverageBuy$20.00High
3/17/2020Cantor FitzgeraldReiterated RatingOverweightLow
3/17/2020Stifel NicolausLower TargetBuy$22.00 ➝ $21.00High
1/21/2020HC WainwrightReiterated RatingBuy$35.00Low
12/11/2019HC WainwrightReiterated RatingBuy$35.00Low
11/5/2019CowenReiterated RatingBuyMedium
11/5/2019HC WainwrightBoost TargetBuy$28.00 ➝ $35.00Medium
10/2/2019OppenheimerLower Target$30.00 ➝ $20.00Low
9/9/2019Janney Montgomery ScottInitiated CoverageBuyHigh
9/4/2019HC WainwrightReiterated RatingBuy$28.00Medium
8/12/2019HC WainwrightReiterated RatingBuy$27.00Low
5/9/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
3/15/2019Cantor FitzgeraldReiterated RatingOverweightHigh
2/26/2019OppenheimerSet TargetBuy$30.00Low
2/26/2019Cantor FitzgeraldReiterated RatingBuyHigh
2/4/2019Cantor FitzgeraldInitiated CoverageBuy$27.00High
1/13/2019OppenheimerSet TargetBuy$30.00Low
11/11/2018OppenheimerInitiated CoverageBuy$30.00Medium
10/16/2018Bank of AmericaDowngradeNeutral ➝ Underperform$19.00 ➝ $9.00High
9/30/2018OppenheimerSet TargetBuy$30.00Medium
9/27/2018Cantor FitzgeraldSet TargetBuy$27.00High
8/10/2018OppenheimerSet TargetBuy$30.00Low
8/9/2018Cantor FitzgeraldReiterated RatingBuy$27.00Low
7/17/2018Cantor FitzgeraldReiterated RatingBuy$27.00Medium
7/16/2018OppenheimerSet TargetBuy$30.00Medium
7/9/2018OppenheimerSet TargetBuy$30.00Low
7/9/2018Cantor FitzgeraldSet TargetBuy$27.00High
6/11/2018Cantor FitzgeraldReiterated RatingBuy$27.00Medium
5/23/2018OppenheimerSet TargetBuy$30.00High
5/23/2018Cantor FitzgeraldSet TargetBuy$27.00High
5/13/2018OppenheimerSet TargetBuy$30.00Medium
5/11/2018HC WainwrightInitiated CoverageBuy$28.00High
5/10/2018Cantor FitzgeraldSet TargetBuy$27.00High
5/3/2018OppenheimerSet TargetBuy$30.00Low
4/30/2018Cantor FitzgeraldSet TargetBuy$27.00High
4/12/2018Cantor FitzgeraldSet TargetBuy$27.00High
4/3/2018OppenheimerSet TargetBuy$30.00High
4/2/2018Cantor FitzgeraldReiterated RatingBuy$27.00High
3/20/2018OppenheimerReiterated RatingBuyLow
2/8/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$27.00Medium
1/11/2018OppenheimerSet TargetBuy$30.00High
12/18/2017OppenheimerSet TargetBuy$30.00High
12/11/2017OppenheimerSet TargetBuy$30.00High
11/27/2017Bank of AmericaInitiated CoverageNeutralHigh
11/27/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$26.00High
11/27/2017CowenInitiated CoverageOutperformHigh
11/27/2017OppenheimerInitiated CoverageBuy$30.00High
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/8/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/7/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 6 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 6 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Spero Therapeutics logo
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.15
Low: $2.02
High: $2.24

50 Day Range

MA: $1.10
Low: $0.68
High: $2.20

52 Week Range

Now: $2.15
Low: $0.68
High: $18.84

Volume

69,522 shs

Average Volume

23,121,906 shs

Market Capitalization

$75.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Spero Therapeutics?

The following equities research analysts have issued reports on Spero Therapeutics in the last year: Berenberg Bank, Cantor Fitzgerald, Cowen Inc, Evercore ISI, and HC Wainwright.
View the latest analyst ratings for SPRO.

What is the current price target for Spero Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Spero Therapeutics in the last year. Their average twelve-month price target is $6.33, suggesting a possible upside of 194.6%. Evercore ISI has the highest price target set, predicting SPRO will reach $8.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $5.00 for Spero Therapeutics in the next year.
View the latest price targets for SPRO.

What is the current consensus analyst rating for Spero Therapeutics?

Spero Therapeutics currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPRO will outperform the market and that investors should add to their positions of Spero Therapeutics.
View the latest ratings for SPRO.

What other companies compete with Spero Therapeutics?

Other companies that are similar to Spero Therapeutics include BioVie, Eyenovia, Trevi Therapeutics, Reneo Pharmaceuticals and Genprex. Learn More about companies similar to Spero Therapeutics.

How do I contact Spero Therapeutics' investor relations team?

Spero Therapeutics' physical mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company's listed phone number is (857) 242-1600 and its investor relations email address is [email protected] The official website for Spero Therapeutics is sperotherapeutics.com. Learn More about contacing Spero Therapeutics investor relations.